Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Change in Cash (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Change in Cash for 14 consecutive years, with -$4.6 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 51.76% to -$4.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$7.2 million through Dec 2025, up 9.08% year-over-year, with the annual reading at -$7.2 million for FY2025, 9.08% up from the prior year.
  • Change in Cash hit -$4.6 million in Q4 2025 for Corcept Therapeutics, down from $22.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $233.6 million in Q1 2023 to a low of -$127.6 million in Q2 2023.
  • Historically, Change in Cash has averaged $2.2 million across 5 years, with a median of -$2.7 million in 2021.
  • Biggest five-year swings in Change in Cash: soared 2107.68% in 2022 and later tumbled 506.64% in 2023.
  • Year by year, Change in Cash stood at -$17.1 million in 2021, then skyrocketed by 194.23% to $16.1 million in 2022, then surged by 47.65% to $23.8 million in 2023, then plummeted by 140.52% to -$9.6 million in 2024, then surged by 51.76% to -$4.6 million in 2025.
  • Business Quant data shows Change in Cash for CORT at -$4.6 million in Q4 2025, $22.4 million in Q3 2025, and $12.9 million in Q2 2025.